期刊文献+

急性冠状动脉综合征患者血清肿瘤坏死因子-α和白细胞介素-18的变化及临床意义 被引量:7

Clinical significance of tumor necrosis factor-α and Interleukin-18 in patients with acute coronary syndrome
下载PDF
导出
摘要 目的探讨血清肿瘤坏死因子-α和白细胞介素-18在急性冠状动脉综合征患者血清中含量的变化及其临床意义。方法选取急性心肌梗死患者40例、不稳定型心绞痛患者36例、稳定型心绞痛患者30例和非冠心病患者27例为研究对象,AMI组、UAP组和SAP组根据冠状动脉造影结果分为单支病变组26例、双支病变组47例和三支病变组33例。采用放射免疫分析法分别测定血清TNF-α和IL-18含量并与病情程度和病变冠脉支数进行比较分析。结果①AMI组血清TNF-α和IL-18水平显著高于UAP组、SAP组和对照组(均P<0.01),UAP组显著高于SAP组和对照组(均P<0.01),SAP组血清TNF-α水平与对照组无差异(P>0.05),但IL-18水平显著高于对照组(P<0.01);②对照组血清TNF-α和IL-18水平显著低于单支、双支和三支病变组(均P<0.01),单支病变组显著低于双支和三支病变组(均P<0.01),双支病变组血清TNF-α水平与三支病变组无差异(P>0.05),但IL-18水平显著低于三支病变组。结论TNF-α和IL-18与ACS冠脉病变密切相关并介导了动脉粥样斑块的易损和破裂,其血清水平变化可作为冠状动脉粥样硬化斑块炎症反应程度和不稳定破裂的观察指标并有助于诊断和预测ACS的发生、发展和预后。 Objective To investigate the changes of serum tumor necrosis factor-α and interleukin-18 and their clinical significance in patients with acute coronary syndrome. Methods 40 patients with acute myocardial infarction and 36 patients with unstable angina pectoris and 30 patients with stable angina pectoris (SAP group) and another 27 patients without coronary heart disease were included in this study. Patients in AMI group, UAP group and in SAP group were divided into three groups as a single-vessel disease group (n = 26),a double-vessel disease group (n = 47) and a triple-vessel disease group (n = 33) according to the results of coronary angiography.The concentrations of serum TNF-α and IL-18 were determined by radioimmunoassay and were analyzed with the severity of ACS.Results (1)The concentrations of serum TNF-α and IL-18 in AMI group were significantly higher than that of the UAP group,the SAP group and the control group (all P 〈 0.01 ) and in UAP group were significantly higher than that of the SAP group and the control group (all P 〈 0.01 ). There were no differences of serum TNF-α comparing between the SAP group and the control group (all P 〉 0.05) but the concentrations of senun IL-18 in SAP group were obviously higher than that of the control group ( all P 〈 0.01 ). (2) The concentrations of serum TNF-α and IL-18 in control group were significantly lower than that of the single-vessel disease group, the double-vessel disease group and the triple-vessel disease group(all P 〈 0.01 ) and in single-vessel disease group were significantly lower than that of the double-vessel disease group and the triple-vessel disease group (all P 〈 0.01 ). There were no differences of serum TNF-α comparing between the double-vessel disease group and the triple-vessel disease group (all P 〉 0.05) but the concentrations of serum IL-18 in double-vessel disease group were obviously lower than that of the triple-vessel disease group (all P 〈 0.01 ). Conclusion TNF-α and IL-18 which are related with the disruption of arterial atheromatous plaque are involved in the coronary artery lesion of ACS. The concentrations of serum TNF-α and IL-18 are important risk and predictive factors for patients with ACS, which are positively correlated with the severity of ACS.
出处 《中国实验诊断学》 北大核心 2009年第9期1158-1160,共3页 Chinese Journal of Laboratory Diagnosis
关键词 急性冠状动脉综合征 肿瘤坏死因子-α 白细胞介素-18 acute coronary syndrome (ACS) tumor necrosis factor-α (TNF-a) interleukin-18 (IL-18)
  • 相关文献

参考文献8

二级参考文献64

  • 1黄炜,陈清枝,燕宪亮,王然,张颖.C-反应蛋白白细胞介素-6和肿瘤坏死因子-α在冠心病中的变化[J].临床心血管病杂志,2004,20(7):398-400. 被引量:29
  • 2李闻文.细胞因子的产生[J].上海医学检验杂志,2002,15(2):201-201.
  • 3Ridker PM,Rifai N,Pfeffer M,et al.Elevation of tumor necrosis factoralpha and increased risk of recurrent coronary events after myocardial infarction[J].Ciriculation,2000,101 (18):2149.
  • 4Isner JM,Kearney M,Bortman S,et al.Apoptosis in human atherosclerosis and restenosis[J].Circulation,1995,91 (11):2703.
  • 5Brown DL,Hibbs MS,Kearney M,et al.Identification of 92-KD gelatinase in human coronary atherosclerotic lesions[J].Circulation,1995,91(8):2125.
  • 6Calis ZS,Sukhoua GK,Lark MW,et al.Increased expression of matrix metal-loproreinases and matrix degrading activity[J].In vulnerable regions of human atherosclerotio plaques[J].J Clin lvest,1994,94(9):2493.
  • 7Miyao Y,Yasue H,Ogawa H,et al.Eluated plasma Il-6 levels in patients with acute myocardial infarction[J].Am Heart J,1993,126(6):1299.
  • 8Thompson SG,Kienast J,Pyke SD,et al.Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris[J].N Engl J Med,1995,332(10):635.
  • 9Kuller LH,Tracy RP,Shaten J,et al.Relationsnip of C-reactive protein and coronary heart disease in the MRFIT nested case-control study[J].Am J Epidemiol,1996,144(6):537.
  • 10Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology, 2000,94 ( 1 ) :31-35.

共引文献9467

同被引文献67

  • 1黄昱刚,陈晓明.冠心病患者尿微量白蛋白检测的临床意义[J].临床医学工程,2010,17(6):48-49. 被引量:4
  • 2杜宇虹,王红.冠心病心绞痛患者血清CRP测定的临床应用[J].现代预防医学,2005,32(7):840-840. 被引量:6
  • 3吕琳,鹿克风,罗静,郭玲.氟伐他汀对兔动脉粥样硬化血管壁NF-κB和PDGF表达的影响[J].临床心血管病杂志,2005,21(8):478-481. 被引量:8
  • 4无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2087
  • 5Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease : application to clinical and public health prac- tice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association [ J]. Circu- lation ,2003 ; 107 ( 3 ) :499-511.
  • 6Tenge C, Sundborger A, Jawien J, et al. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression inde- pendently of T cells[ J]. Arterioscler Thromb Vasc Biol,2005 ;25:791-6.
  • 7Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho- kinase suppresses left ventricular remodeling after myocardial infarction in mice[ J]. Circulation,2004 ; 109:2234-9.
  • 8Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho- kinase induces a regression of arteriosclerotic coronary lesions in a por- cine model in vivo[J]. Cardiovasc Res,2001 ;51 ( 1 ) : 169-77.
  • 9Satoh S, Ikegaki I,Toshima Y, et al. Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats [ J]. Life Sci, 2002 ;72 : 103-12.
  • 10Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of car- diovascular diseases[J]. J Cardiovasc Pharmacol,2002;39(3) :319-27.

引证文献7

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部